Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Verrica Pharmaceuticals (NASDAQ:VRCA) from a sell rating to a strong sell rating in a research report released on Saturday.

Other equities research analysts also recently issued reports about the company. HC Wainwright started coverage on Verrica Pharmaceuticals in a report on Tuesday, May 26th. They set a “buy” rating and a $12.00 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. Finally, Zacks Research upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $14.50.

Verrica Pharmaceuticals Trading Up 2.3%

NASDAQ:VRCA opened at $4.97 on Friday. The firm has a market cap of $85.38 million, a P/E ratio of -2.98 and a beta of 1.49. The company has a current ratio of 1.45, a quick ratio of 1.98 and a debt-to-equity ratio of 0.18. The stock’s 50 day simple moving average is $5.70 and its 200-day simple moving average is $5.96. Verrica Pharmaceuticals has a 12-month low of $3.28 and a 12-month high of $9.82.

Institutional Trading of Verrica Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC increased its holdings in Verrica Pharmaceuticals by 75.1% in the fourth quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock valued at $9,298,000 after buying an additional 479,732 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Verrica Pharmaceuticals during the 4th quarter worth approximately $99,000. Man Group plc acquired a new stake in shares of Verrica Pharmaceuticals in the 4th quarter worth approximately $94,000. Walleye Capital LLC acquired a new stake in shares of Verrica Pharmaceuticals in the 4th quarter worth approximately $127,000. Finally, Beck Mack & Oliver LLC acquired a new stake in shares of Verrica Pharmaceuticals in the 4th quarter worth approximately $100,000. Hedge funds and other institutional investors own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.